CXCL13 and prostate carcinoma: Gα13 binds to CXCR5 in response to CXCL13 treatment and promotes prostate cancer cell movements; however, silencing Gα13 does not affect CXCL13-dependent cell invasion (El-Haibi et al., 2013).